BamSEC and AlphaSense Join Forces
Learn More

BioMarin Pharmaceutical Inc.

NASDAQ: BMRN    
Share price (12/23/24): $66.27    
Market cap (12/23/24): $12.6 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 2 pages BioMarin Pharmaceutical Inc. Summary of Independent Director Compensation
12/34/56
EX-10.1
from 8-K 148 pages Material contract
12/34/56
EX-10.2
from 10-Q ~1 page Biomarin Pharmaceutical Inc. Summary of Independent Director Compensation
12/34/56
EX-10.1
from 10-Q 2 pages Amendment to Consulting Agreement
12/34/56
EX-10.1
from 10-Q 2 pages Delivered by E-Mail April 11, 2024 Biomarin Pharmaceutical Inc. 105 Digital Drive Novato, California 94949 Attention: Eric Davis, Chief Legal Officer Email: Edavis@bmrn.com Dear Sirs / Madams
12/34/56
EX-10.1
from 8-K 22 pages Cooperation Agreement
12/34/56
EX-10.3
from 8-K 13 pages Employment Agreement
12/34/56
EX-10.2
from 8-K 11 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 8 pages Separation Agreement and General Release
12/34/56
EX-10.1
from 10-Q 22 pages Biomarin Pharmaceutical Inc. 2017 Equity Incentive Plan, as Amended April 3, 2023
12/34/56
EX-10.37
from 10-K 6 pages Biomarin Pharmaceutical Inc. 2017 Equity Incentive Plan Stock Option Award Agreement
12/34/56
EX-10.36
from 10-K 5 pages Biomarin Pharmaceutical Inc. 2017 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.35
from 10-K 4 pages Biomarin Pharmaceutical Inc. 2017 Equity Incentive Plan Restricted Stock Unit Award Agreement
12/34/56
EX-10.2
from 10-Q ~5 pages Biomarin Pharmaceutical Inc. Summary of Independent Director Compensation
12/34/56
EX-10.1
from 10-Q 1 page Third Amendment to the Amended and Restated Biomarin Pharmaceutical Inc. Nonqualified Deferred Compensation Plan (The “Plan”) (As Amended and Restated on October 7, 2014) Effective Date: October 4, 2022
12/34/56
EX-10.1
from 10-Q 25 pages Certain Information, Identified By, and Replaced With, a Mark of “[***]” Has Been Excluded From This Exhibit Because It Is Both Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.32
from 10-K 2 pages Second Amendment to the Amended and Restated Biomarin Pharmaceutical Inc. Nonqualified Deferred Compensation Plan (The “Plan”) (As Amended and Restated on October 7, 2014) Effective Date: October 5, 2021
12/34/56
EX-10.1
from 10-Q 148 pages Material contract
12/34/56
EX-10.32
from 10-K 6 pages Part-Time Employment Agreement
12/34/56
EX-10.1
from 10-Q/A ~5 pages Biomarin Pharmaceutical Inc. Summary of Independent Director Compensation
12/34/56